Shaping the Future of Innovation: Early-Stage Venture Capital for Accredited Investors
This content is informational in nature. An offer or solicitation to acquire interests may only be made through the Private Placement Memorandum (PPM) in accordance with applicable securities laws. Participation is limited to Accredited Investors as defined under SEC Rule 501 of Regulation D. Past performance does not guarantee future results.
▶ Provide funding in exchange for equity.
▶ Aiming for significant returns as the
company scales.
▶ Higher-risk, higher-reward strategy
fuels innovation, disrupts industries,
and creates market leaders.
Participation in Prevail Venture Capital Fund I, LP is limited to accredited investors as defined by the U.S. Securities and Exchange Commission (SEC) under Rule 501 of Regulation D. To qualify as an accredited investor, an individual must meet at least one of the following criteria:
Most business owners and entrepreneurs served by Prevail qualify as accredited investors based on income or net worth. If you are uncertain whether you qualify, Prevail advisors can walk you through the assessment before you review the fund’s PPM.
Prevail Venture Capital Fund I is particularly well suited for business owners and high-net-worth individuals who:
Venture capital is not appropriate for investors who require near-term liquidity, have a low risk tolerance, or are allocating funds they cannot afford to lose. Prevail will discuss suitability openly before any investment is recommended.
The following terms appear throughout this fund’s materials. Each is defined here in plain language so that business owners evaluating this opportunity can make informed decisions without prior venture capital experience.
Venture capital is a form of private equity investment in which a fund provides capital to high-growth, early-stage companies that are privately owned — typically in exchange for an equity stake (ownership percentage) in the company. Unlike publicly traded stocks, venture capital investments are illiquid: investors cannot sell their stake on an exchange. Returns are realized when the company is acquired, merges, or goes public (IPO). The venture capital model is designed around a power law: a small number of highly successful investments generate the majority of the fund’s total return.
MOIC measures how much money a fund returns relative to the capital invested, expressed as a multiple. A MOIC of 4.0x means that for every $1 invested, the fund returns $4. Prevail Venture Capital Fund I targets a MOIC of 4.0x–5.0x over its 6–8 year fund life. MOIC does not account for the time value of money — it is a gross return multiple, not an annualized rate. It is best read alongside IRR, which adjusts for timing.
IRR is the annualized rate of return on an investment, accounting for the timing of cash flows in and out of the fund. A fund that returns 4x over 8 years has a different IRR than one that returns 4x over 4 years — the faster return produces a higher IRR because capital is not tied up as long. Prevail’s focus on returning initial capital within 36–42 months is specifically designed to enhance IRR by reducing the time capital is deployed before investors begin receiving distributions. This mechanism is called capital recycling.
A venture capital fund is structured as a Limited Partnership (LP). Investors in the fund are called Limited Partners (LPs — they provide capital and share in the fund’s returns, but have no role in day-to-day investment decisions and bear limited personal liability. The fund manager — in this case, Prevail Venture Capital — is the General Partner (GP). The GP makes all investment decisions, manages portfolio companies, and is responsible for the fund’s strategy and operations. GPs typically earn a management fee (commonly 2% of committed capital annually) and carried interest (commonly 20% of profits above a hurdle rate).
Venture capital funds are organized by vintage year — the year in which the fund began making investments. Vintage year matters because the economic environment at the time of investment significantly affects returns. Funds with a 2008 or 2009 vintage, for example, invested at historically low valuations during the financial crisis and produced strong returns as markets recovered. Prevail Venture Capital Fund I is the firm’s inaugural fund, establishing its first vintage in the current market environment, which the team believes presents favorable conditions after a period of compressed valuations in 2022–2023.
Follow-on capital refers to additional investment made into a portfolio company after the initial investment. Prevail Venture Capital Fund I reserves 25% of each stage allocation for follow-on investments — meaning if a portfolio company performs well and needs additional capital for growth, the fund can participate in subsequent funding rounds without depleting the fund’s capacity to make new investments. Follow-on capital protects the fund’s ownership percentage (preventing dilution) in its highest-performing companies.
Capital recycling is the practice of returning initial invested capital to LPs as early as fund performance allows, then redeploying it into new investments — effectively using the same capital more than once within the fund’s life. Prevail targets returning initial capital within 36–42 months. This accelerates IRR by reducing the time capital is deployed, and allows investors to re-evaluate their allocation position earlier in the fund’s life rather than waiting for a terminal distribution at fund close.
Carried interest (commonly called ‘carry’) is the share of a fund’s profits paid to the General Partner above a specified hurdle rate. It aligns the GP’s incentives with investors: the GP only earns carry if the fund performs above the hurdle. Prevail’s carry structure, management fee, and hurdle rate are specified in the fund’s Private Placement Memorandum (PPM), available to accredited investors upon request.
A Private Placement Memorandum is the legal disclosure document for a private securities offering. It contains the fund’s full terms, risk factors, investment strategy, fee structure, management team backgrounds, and subscription procedures. By SEC regulation, all investors must read the PPM before investing. Prevail provides the PPM to qualified accredited investors upon request through the contact page.
The following metrics represent Prevail’s targets for Fund I. These are objectives, not guarantees. All investment involves risk, including the possible loss of principal.
Fund I targets investments across three stages of early-stage company development. The stage breakdown below reflects the fund’s allocation strategy and estimated deal parameters. All figures are targets; actual deployment will vary based on deal flow and market conditions.
| Stage / Round | % of Fund Allocated | Estimated Deal Size | Follow-On Reserve | Est. Companies |
|---|---|---|---|---|
| Seed | 25%–35% | $250K–$2.5MM | 25% | 10–15 companies |
| Seed+ | 25%–35% | $1.0MM–$4.0MM | 25% | 3–10 companies |
| Series A | 25%–35% | $2.0MM–$5.0MM | 25% | 2–5 companies |
Each stage allocation includes a 25% follow-on reserve, meaning Prevail retains capital to participate in subsequent funding rounds for top-performing portfolio companies. This protects investor ownership percentage in the fund’s strongest performers as those companies scale.
Prevail Venture Capital Fund I, LP is an inaugural fund — a dynamic and diversified investment platform designed to fuel the next generation of high-growth companies. The fund targets high-impact, early-stage ventures poised to disrupt industries and redefine their markets. Investors gain access to visionary entrepreneurs, cutting-edge technologies, and companies with demonstrable competitive advantages in large and growing markets. Learn more about our broader investment strategies.
Private venture capital funds are organized by vintage year, and the environment for new fund vintages has improved significantly after a correction period in 2022–2023, when startup valuations compressed substantially across most sectors. Prevail believes the current environment offers favorable entry valuations for early-stage companies — analogous to the conditions that produced strong returns for 2009 and 2010 vintage funds that invested at the trough of the financial crisis.
The fund builds concentrated, significant positions in high-growth companies, then engages actively with founders to drive scalable expansion and position for high-value exit events. Rather than taking passive minority stakes, Prevail’s team provides hands-on operational support, strategic planning, and network access — with the goal of maximizing the value of each portfolio company at exit.
Prevail’s objective is to return initial capital to investors as fast as fund performance allows — targeting the 36–42 month range — then continue to participate in the remaining upside as portfolio companies progress toward exit. This rapid capital recycling is designed to enhance IRR by increasing the velocity of deployed capital, mitigate overall risk through earlier capital recovery, and maximize compounding returns over the fund’s full life. For investor inquiries, visit our contact page.
Fund I prioritizes three primary sectors: healthcare, technology, and consumer products. The selection of these sectors reflects the team’s expertise, current market opportunity, and demographic tailwinds:
Healthcare and life sciences: the U.S. healthcare market exceeded $4.5 trillion in 2022 (CMS National Health Expenditure Data) and continues to grow. Technological disruption in diagnostics, medical devices, regenerative medicine, and digital health creates early-stage investment opportunities that are less correlated with public market cycles. Prevail’s portfolio companies Mimix AWC (regenerative wound care) and Coologics (women’s health medical device) are examples of this thesis.
Technology and defense technology: artificial intelligence, generative audio, defense modernization, and data infrastructure represent areas where early-stage companies can build significant proprietary advantages before institutional capital arrives at scale. Portfolio companies svexa (physiological AI), insoundz (generative AI audio), BlackLake (defense infrastructure), and Tiberius (defense weapons systems) represent this thesis.
Consumer products and wellness: brands with strong community identity and recurring purchase behavior can scale efficiently with the right capital and operational support. Portfolio company Prosupps (fitness supplements) and Cloud (water filtration) represent the consumer thesis.
Emerging opportunities: the fund maintains allocation flexibility for emerging sectors outside the three primary verticals — capturing innovation that does not fit neatly into existing categories. MDU Homes (modular luxury housing), Brightwater (industrial water treatment), Belong (fintech / entertainment economy), and Midwest Games (independent game publishing) represent this diversified approach.
Business owners evaluating Prevail Venture Capital Fund I are often simultaneously considering private equity, real estate, public equities, and angel investing. The table below compares these alternatives across the dimensions that matter most for portfolio construction and long-term wealth building.
| Feature | Venture Capital (LIRP) | Private Equity | Public Equities | Real Estate | Angel Investing |
|---|---|---|---|---|---|
| Stage of investment | Early-stage startups (Seed to Series A) | Mature companies / buyouts | Public markets | Physical / income-producing assets | Pre-seed / idea stage |
| Typical hold period | 6–8 years | 4–7 years | Flexible | 5–10 years | 7–10+ years |
| Return potential (MOIC) | 4x–10x+ (top quartile) | 2x–4x | 1.5x–2x (10yr avg) | 1.5x–3x | 10x+ (very few succeed) |
| Diversification | High — 20–35 companies | Low — concentrated | High via index | Asset class specific | Very low — 1 or few bets |
| Liquidity | Illiquid — 6–8 year lock-up | Illiquid — 4–7 years | Highly liquid | Low to moderate | Illiquid — long hold |
| Minimum investment | Accredited investors only | Often $1MM+ | No minimum | Varies widely | Typically $25K–$100K |
| Manager involvement | Active — board seats, mentorship | Operational control | None (passive) | Property management | Advisory / informal |
| Tax planning integration | Yes — coordinated with LP tax strategy | Sometimes | Limited | Yes (depreciation, 1031) | Rarely |
Venture capital is not superior to all other asset classes in every dimension. It offers the highest potential return per dollar invested — but requires the longest lock-up, the highest risk tolerance, and the willingness to accept that some investments will return zero. The appropriate allocation to venture capital within a broader portfolio depends on an investor’s liquidity needs, time horizon, existing asset mix, and tax situation. Prevail evaluates these factors individually for each client before making any recommendation.
Most venture capital funds provide capital and board representation, then step back. Prevail’s approach is different: the team treats each portfolio company relationship as an active operational partnership, not a passive equity stake. For many founders, securing funding is the primary focus at the start. But the real challenge begins after the wire hits — transforming capital into a thriving, scalable business. Prevail’s value proposition is that it provides not just capital, but the expertise to help founders navigate that transition.
Specifically, Prevail’s team offers:
Prevail Venture Capital Fund I is led by a team with direct experience building, scaling, and exiting businesses — not just investing in them. This distinction matters: operators who have built companies understand the specific challenges founders face in ways that career financiers often do not.
Kerry Lawing, CEO: over 35 years of experience building, scaling, and successfully exiting businesses across multiple industries. His track record as a founder and operator — not just an investor — is the foundation of Prevail’s founder-first approach.
Andrew Stafford, President: 4th-generation family business operator who co-launched three startups and drove revenue growth in two separate business units from $5MM to $30MM and $60MM to $100MM respectively within three years — demonstrating a specific capacity to accelerate growth in businesses at the stage Prevail targets.
Matthew Burleigh, CFA, Senior Portfolio Manager: Chartered Financial Analyst with over 25 years of buy-side investment management experience, with deep expertise in sectors significantly influenced by M&A cycles, financial modeling, valuation analysis, and market forecasting.
Timothy Bledsoe, Partner (Private Capital Fund): an early member of Salient Surgical — a platform medical device company acquired by Medtronic for $645 million in 2011 — and led development of a private equity-backed high-acuity surgery center business that transacted in 2022.
Learn more about our broader investment strategies.
Fund I targets 20–35 total investments across seed, seed+, and Series A stages, with deal sizes ranging from $250,000 to $5,000,000 depending on stage. This breadth is deliberate: venture capital returns follow a power law distribution, meaning a small number of investments produce the majority of total returns. A fund of 20–35 companies provides sufficient diversification to capture those outlier outcomes even if the majority of investments return modest multiples or fail.
Within the portfolio, concentration risk is managed by:
The following companies represent current portfolio holdings as of the fund’s initial deployment phase. Each was selected based on Prevail’s evaluation criteria: risk profile, structure, sponsor quality, sector fit, and growth trajectory. Descriptions reflect publicly available information about each company’s mission and market.
| Company | Location | Sector | What They Do |
|---|---|---|---|
| Prosupps | Dallas, TX | Health & Consumer | Supplements brand built by fitness enthusiasts, serving individuals at every stage of their fitness journey. |
| BlackLake | Austin, TX | Defense / Technology | Building the infrastructure of a modern defense prime through a diversified, ecosystem-based approach. |
| svexa | Menlo Park, CA | Health Tech / AI | Develops proprietary algorithms and software solutions integrating diverse physiological data sources for performance optimization. |
| Midwest Games | Green Bay, WI | Gaming / Entertainment | Independent game publisher providing publishing support across PC and consoles globally. |
| Mimix AWC | Switzerland | Regenerative Medicine | Redefining wound care and tissue repair using its proprietary Sound-Induced Morphogenesis (SIM) platform. |
| Brightwater | Palm Springs, CA | CleanTech / Water | Patented, chemical-free process treating industrial wastewater and reducing Total Dissolved Solids (TDS) at scale. |
| Cloud | San Diego, CA | Consumer / Water | NSF 58-certified water filtration — removes up to 99% of toxins from tap water. |
| Coologics | Columbus, OH | Women’s Health | First drug-free, faster, and more effective treatment for vaginal infections — a novel medical device approach. |
| insoundz | Tel Aviv, Israel | AI / Audio | Redefining generative AI audio with its award-winning Revive platform for audio enhancement. |
| MDU Homes | Fort Worth, TX | Real Estate / Housing | Redefining luxury living with innovative, minimalistic housing solutions for individuals and developers. |
| Tiberius | Newport Beach, CA | Defense Technology | Next-generation defense company developing advanced weapon systems and software to modernize military operations at scale. |
| Belong | New York, NY | Fintech / Entertainment | Fan-intelligence-led challenger bank focused on the entertainment economy and Gen Z; helps brands monetize fan relationships. |
Portfolio company descriptions reflect publicly available information. Investment in specific portfolio companies is subject to the fund’s investment thesis and due diligence process. Not all companies listed may be current holdings at the time of reading. Contact Prevail for current fund status through the contact page.
Learn more about our broader investment strategies.
The process for investing in Prevail Venture Capital Fund I follows the standard private securities offering framework required by the SEC for Regulation D offerings:
Contact Prevail via the contact page to express interest. A member of the investment team will schedule an introductory call to discuss the fund’s strategy, your investment objectives, and whether this fund is appropriate for your situation.
Prevail will confirm your accredited investor status. This is a legal requirement before you can receive the PPM or proceed with any investment commitment.
Prevail will provide the full PPM, which contains the fund’s complete terms, risk factors, fee structure, and legal disclosures. You must read the PPM before investing — this is required by law and enforced by Prevail as a matter of practice.
Prospective LPs are encouraged to ask questions, review team backgrounds, and consult their CPA and legal counsel before making any investment commitment. Prevail’s advisors are available during this period to answer specific questions about the fund’s strategy and terms.
If you decide to invest, you will complete a subscription agreement specifying your committed capital amount and confirming your accredited investor status. Prevail’s team will guide you through the subscription documentation.
Prevail may call capital in tranches as investment opportunities are identified, rather than requiring the full commitment upfront. The timing and structure of capital calls is described in the PPM.
Minimum investment amount and subscription terms are specified in the PPM. Contact Prevail at rsmith@prevailiws.com to begin the process or visit our investment strategies page for additional insights.
REDEFINING VENTURE CAPITAL: THE PREVAIL WAY
PREVAIL’S OBJECTIVE IS TO RETURN INITIAL CAPITAL BACK TO INVESTORS AS FAST AS THE FUND ALLOWS, WITH A TARGETED RANGE OF 36 TO 42 MONTHS DEPENDING ON PERFORMANCE
▶ This rapid capital recycling enhances IRR.
▶ Accelerates growth by increasing the velocity of money.
▶ Mitigates risk but also maximizes compounding returns.
Kerry Lawing, CEO of Prevail, brings over 35 years of experience in building, scaling, and successfully exiting businesses. Known for his strategic vision and relentless drive, he has a proven track record of accelerating growth and creating lasting impact across multiple industries. His leadership continues to propel Prevail and other entities forward, fostering innovation and long-term value.
Andrew Stafford is a seasoned business leader and financial strategist with a strong background in entrepreneurship and corporate growth. Starting as a 4th generation operator of a family business,
he gained firsthand experience in scaling legacy enterprises. He’s successfully co-launched three startups and led major business units within a $750M company, driving revenue growth in two separate business units from $5M to $30M and $60M to $100M in just three years.
Matthew Burleigh is a Charter Financial Analyst (CFA) with over 25 years of experience in buy-side investment management, focusing on sectors significantly influenced by M&A cycles.
He possesses a deep expertise in financial modeling, valuation analysis, and market forecasting. His proficiency in financial analysis enables him to assess complex investment opportunities, optimize capital allocation, and develop strategic
growth plans.
Timothy Bledsoe is a visionary leader with a strong history of disrupting the healthcare landscape. He was an early member of Salient Surgical, a platform medical device company acquired by Medtronic for $645 million in 2011, and he led the development efforts of a private equity-backed high acuity surgery center business that transacted in 2022. As Co-Founder of NextStage Clinical Research, Tim focuses on bringing cutting-edge research options to patients through partnerships with world-class physicians in their local communities. landscape.
(*) Partners are key relationship consultants and are not direct partners in Prevail Venture Capital Fund I LP or any of its affiliated entities.
Contact Us Today
The information is not an offering to sell a real estate investment. The content is informative in nature and specifics are only available upon request. Investing in real estate involves risk, many times is illiquid, and use should consult your financial professionals before making any investment of this nature.
An offer or solicitation to acquire interests in the investment may only be made by our Private Placement Memorandum (“Memorandum”) in accordance with the terms of all applicable security laws. All information contained herein is subject to and qualified by the contents of the Memorandum. Participation in any securities offering is limited to Accredited investors. Please call to obtain a copy. You must read it before investing. Past performance is no guarantee of future results.
All answers reflect Prevail's investment philosophy and fund structure. For fund-specific legal, tax, and financial details, refer to the Private Placement Memorandum.
Prevail treats venture capital as a long-term, complementary allocation — not a core liquidity source. In a well-constructed portfolio for a business owner, venture capital typically represents 5–15% of investable assets, depending on liquidity needs and time horizon. It functions as a high-return-potential allocation that is deliberately illiquid, positioned alongside more liquid holdings (public equities, bonds) and tax-advantaged vehicles (LIRPs, real estate) to create a diversified return and tax profile. The venture allocation is sized based on what the investor can genuinely commit for 6–8 years without requiring access to those funds.
Prevail evaluates each investment opportunity across four primary dimensions. First, risk profile — the fund assesses market risk (is the sector growing?), execution risk (can this team build this product?), and structural risk (is the cap table and deal structure appropriate for LP investors?). Second, structure — the fund evaluates the terms of the investment, including ownership percentage, pro-rata rights for follow-on rounds, and liquidation preferences. Third, sponsor quality — the founding team’s track record, domain expertise, and character are the single most important factor in early-stage investing; Prevail prioritizes founders with direct industry experience and demonstrated ability to execute. Fourth, strategic fit — the opportunity must align with one of the fund’s target sectors and fit within the portfolio’s existing concentration and stage profile.
Risk assessment in venture capital operates across four layers. Structural risk refers to how the investment is legally structured — ownership terms, rights, and protections. Execution risk evaluates whether the founding team has the specific skills needed to build and scale the business. Concentration risk tracks how much of the fund’s capital is exposed to any single company, sector, or geography — the fund’s 20–35 company target and cross-sector strategy are direct responses to managing concentration. Liquidity risk acknowledges that all venture investments are illiquid by nature, and Prevail manages this by sizing the venture allocation appropriately relative to each investor’s total liquidity position. The 25% follow-on reserve at each stage is an additional risk management tool — it preserves the fund’s ability to support winners without over-committing to early positions.
Venture capital supports two objectives within a broader portfolio: diversification and long-term growth. On diversification, early-stage private company investments have low correlation to public equity markets — a venture portfolio does not necessarily decline when the S&P 500 falls, because portfolio company valuations are not marked to market daily. On long-term growth, the top-quartile return profile of venture capital (MOIC of 3x–5x+ over a fund cycle) provides growth potential that fixed income and even public equities rarely match. For business owners who have built significant wealth in their business — a highly concentrated, illiquid single asset — a venture capital allocation that is diversified across 20–35 companies and multiple sectors can actually reduce overall portfolio risk relative to the starting position.
Allocation to Fund I is determined individually based on three factors. Liquidity needs are assessed first — the fund requires capital that can genuinely be locked for 6–8 years, so Prevail maps each investor’s near-term and medium-term cash requirements before recommending any allocation. Risk tolerance is evaluated in terms of both financial capacity (can the investor afford to lose this allocation?) and psychological tolerance (can the investor commit capital for 8 years without access, through periods of uncertainty about portfolio company performance?). Time horizon is the third factor — investors closer to retirement may have a shorter window to benefit from a venture fund’s full cycle, which affects whether an allocation makes sense at all and at what size.
Prevail is direct about liquidity expectations: capital committed to Fund I should be treated as fully illiquid for the fund’s full life of 6–8 years. There is no secondary market for LP interests, and Prevail does not guarantee any specific distribution timeline. The fund’s objective is to return initial capital within 36–42 months through capital recycling — but this is a target, not a commitment, and depends on portfolio company performance. Investors who need access to these funds within 5 years, or who would experience financial hardship if this allocation returned zero, should not invest. This is not boilerplate — it is the honest assessment Prevail applies to every prospective LP conversation.
Founder evaluation is the most important step in Prevail’s investment process. The team conducts an experience review that covers the founder’s domain expertise, prior entrepreneurial track record, and specific experience in the stage of company they are now building. An alignment assessment evaluates whether the founder’s goals — for the company, for their own financial outcome, and for their relationship with investors — are compatible with the fund’s thesis and LP expectations. An operational evaluation examines whether the founding team has the functional depth needed to execute: product development, sales, finance, and team building. Prevail places particular emphasis on founders who have direct operating experience in their target market, as this reduces execution risk at the most critical early stage.
Ongoing monitoring focuses on three dimensions: performance (is the company hitting milestones?), execution (is the team performing as assessed during diligence?), and strategic relevance (does the company still fit the fund’s thesis given changes in its market?). Prevail maintains active relationships with portfolio company founders — not annual check-in calls, but ongoing advisory involvement where the team’s expertise is useful. This operational engagement gives Prevail earlier visibility into performance issues than a passive LP would have, and the ability to provide support before small problems become structural ones.
Performance is evaluated relative to three benchmarks: against the fund’s stated targets (MOIC 4.0x–5.0x, IRR consistent with 36–42 month capital return), against risk taken (a fund that achieves 3x with excellent capital preservation may outperform one that achieves 4x through excessive concentration in a single winner), and against the fund’s role within each LP’s broader portfolio (did the venture allocation perform its intended diversification and return function?). Prevail does not evaluate venture performance against public equity benchmarks — the asset class is fundamentally different in structure, liquidity, and return profile, and comparing them directly is misleading.
Concentration risk is managed at three levels. At the company level, Prevail limits any single investment to a defined maximum percentage of total fund capital — ensuring that no single company’s failure can materially impair the fund’s overall return. At the sector level, the fund’s three-sector focus (healthcare, technology, consumer) plus emerging opportunities allocation prevents over-exposure to any one industry’s cycle. At the sponsor level, Prevail limits exposure to any single founding team, geographic market, or business model. The fund’s target of 20–35 total investments is specifically calibrated to provide enough diversification to capture power-law outlier returns while managing downside through breadth.
LPs receive structured reporting on a defined schedule, including quarterly updates on portfolio company performance, capital deployment progress, and material developments at individual holdings. For significant events — exits, down rounds, leadership changes, or major milestones — Prevail communicates directly and promptly, not at the next scheduled reporting date. The team believes LPs should have the same material information that shapes Prevail’s own decision-making, delivered clearly and without delay.
Time horizon is the single most important gating factor for any venture capital investment. Private capital requires patience — early-stage companies take 6–10 years to reach exit, and distributions from a fund typically begin after initial capital is returned (targeted at 36–42 months) and then continue as portfolio companies exit over the remaining fund life. An investor who needs capital returned in 3–5 years should not commit to a fund with a 6–8 year life. Prevail evaluates each LP’s full financial picture — including retirement timeline, business sale plans, estate planning needs, and existing liquidity — before recommending any allocation to Fund I.
Tax considerations are evaluated before allocation and monitored throughout the investment lifecycle. Specific areas of coordination include: investment structure (LP interests may generate K-1 income or loss depending on fund activity, which affects an investor’s annual tax filing); timing of capital calls relative to the investor’s income in a given year; and distribution timing, which Prevail considers when structuring exits to give LPs the best possible tax position on returned capital and carried gains. For business owners who also hold tax-free vehicles (LIRPs) through Prevail’s wealth management practice, venture capital distributions can be coordinated with tax-free income sources to manage overall taxable income in retirement. This integration — investment, tax, and distribution planning as a unified strategy — is one of Prevail’s core differentiators from standalone VC funds.
Two misconceptions are most damaging to investors evaluating venture capital for the first time. The first is that venture capital is risk-free because ‘startups are exciting and everyone is talking about AI.’ Venture capital is one of the highest-risk asset classes available — the majority of early-stage companies fail to return invested capital, and even top-performing funds rely on a small number of outlier successes to generate their overall return. The second misconception is the opposite: that venture capital is universally inappropriate for non-institutional investors. Accredited investors with appropriate liquidity, time horizon, and risk tolerance can access the same early-stage investment opportunities as institutional funds — and Prevail was specifically designed to make that access available to business owners and entrepreneurs who have built the wealth to qualify but historically lacked the relationships to participate.
Prevail recommends against any venture capital allocation for investors in four situations: when the investor requires liquidity from the proposed allocation within 5 years; when the investor’s overall financial position cannot absorb the complete loss of the allocation without material impact on their retirement or financial security; when the investor has a fundamentally low risk tolerance — meaning they would lose sleep or make reactive decisions if the fund reported poor interim results; or when the investor does not have sufficient investable assets to diversify the venture allocation within a broader portfolio (concentrating a large percentage of total wealth in a single venture fund amplifies rather than manages risk). Prevail’s advisors discuss these conditions openly in every initial conversation — venture capital is appropriate for some clients and not others, and there is no benefit to recommending it to investors for whom it creates more risk than it resolves.
Investment advisory services are offered through Prevail Innovative Wealth Advisors, LLC (PIWA), a federally registered investment advisor (SEC). Venture capital fund management services are offered through Prevail Venture Capital. This content is informational in nature and does not constitute an offer to sell or a solicitation to buy any security. An offer or solicitation may only be made through the fund's Private Placement Memorandum in accordance with applicable securities laws. Participation in the fund is limited to Accredited Investors as defined under SEC Rule 501 of Regulation D. Prevail does not provide tax or legal advice — consult your CPA and attorney before making any investment decision. Past performance does not guarantee future results. All investment involves risk, including the possible loss of the entire amount invested.
The information regarding the $645 million Medtronic acquisition of Salient Surgical is sourced from publicly available press releases and news coverage of that transaction. Timothy Bledsoe's involvement as described represents his stated background. Prospective investors should independently verify material biographical claims through the PPM and direct conversation with the team.Contact: Regan Smith, Investor Relations — Prevail Private Capital Fund I LP — rsmith@prevailiws.com — (913) 295-9500 — 4745 W 136th St, Overland Park, KS
